News and Events

While visiting her son at Duke University Hospital's pediatric cardiac intensive care unit, one mother would take out her drawing pad and begin Bible journaling. It's a practice that involves writing and illustrating inspirational religious quotes.

In a recent study, Duke researchers tested whether a single infusion of a unit of a child’s own or donor cord blood could improve social communication skills in children between the ages of 2-7 diagnosed with autism spectrum disorder.

The School of Medicine has assembled a “SWAT Team” of individuals in various research support offices to facilitate proposal preparation and submission for investigators who seek funding for COVID-19 research.

Congratulations to Genevieve Fouda, MD, PhD, associate professor of pediatrics in the Division of Infectious Diseases, for receiving an R21 grant entitled, Molecular signatures of broad neutralization in HIV infected children

Sujay Kansagra, MD, decided to focus on neurology and pediatric sleep as a medical student, both because of the room the field offered for research and education.

Two members of the Department of Pediatrics and one member of the Department of Medicine have received Colin's Kids Foundation awards.

Family life, regardless of where you started, looks a lot different for almost everyone now than it did at the beginning of March, when the coronavirus threat was still something to be watched from afar.

This week’s Staff Spotlight shines on Lisa Rasbach, PhD, CPNP, a nurse practitioner in the Division of Pediatric Endocrinology.

A pug in North Carolina named Winston has tested positive for the coronavirus in what is apparently the first known case in which the virus was detected in a dog in the United States, researchers at Duke University said on Tuesday.

Members of the Pediatric Trials Network (PTN) have worked to collaboratively to establish an extended component of the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02) to focus on six drugs that have the potential to be involved in the treatment of COVID-19, including azithromycin, chloroquine, hydroxychloroquine, lopinavir/ritonavir, ribavirin, and tocilizumab.